Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG

Fátima Reyes,Reinier Borrero,Sonsire Fernández,Armando Acosta,Giselle Reyes,Alina Puig,Ramlah Kadir,José Luis Pérez,María E Sarmiento,Caridad Zayas,Mohd Nor Norazmi,Yanely Tirado

doi:10.1186/1471-2172-14-s1-s7

Fátima Reyes, Reinier Borrero + Show 10 more

Open Access

https://doi.org/10.1186/1471-2172-14-s1-s7

Copy DOI

Journal: BMC immunology	Publication Date: Feb 1, 2013
Citations: 20	License type: CC BY 2.0

Affiliation: Finlay Institute, Universiti Sains Malaysia

Abstract

The only currently available vaccine against tuberculosis (TB) is Mycobacterium bovis Bacille Calmette-Guerin (BCG), which has inconsistent efficacy to protect against the disease in adults. M. tuberculosis (MTB) cell wall components have been implicated in the pathogenicity of TB and therefore have been a prime target for the identification and characterization of cell wall proteins with potential application in vaccine development. In this regard, proteoliposomes (PLs) derived from mycobacteria containing lipids and cell wall proteins could be potential vaccine candidates against TB. In the present study PLs derived from BCG were prepared. These homogeneous population of spherical microparticles was then immunized into Balb/c mice. Sera of immunized animals showed high IgG response and strong cross-reactivity against different MTB antigens.These results showed that BCG PLs could be potential vaccine candidates against TB.

Highlights

TB remains a major infectious disease which causes high morbidity and mortality worldwide [1]
Since the Bacille Calmette-Guerin (BCG) genome is more than 90% homologous to that of M. tuberculosis (MTB) [7], it is reasonable to assume that BCG PLs can be potential vaccine candidates against TB
Preparation and partial characterization of BCG PLs The molecular size of BCG PLs was estimated by the coefficient of Ve/Vt relation obtained from size exclusion chromatography

Summary

Introduction

TB remains a major infectious disease which causes high morbidity and mortality worldwide [1]. BCG, an attenuated strain of Mycobacterium bovis (Mb), is the current vaccine approved for human use against TB. It is most effective in protecting children from the disease; while its efficacy in adults is poor especially against pulmonary TB, proving the prevailing necessity to obtain a more effective vaccine [2]. Many studies support the role of mycobacterial cell wall components in the development of TB pathogenesis [4]. Since mycobacterial cell wall components have been suggested to be potential targets for the development of new TB vaccine formulations, we attempted to use PLs from BCG to determine the immunogenicity and cross-reactivity of these microparticles against MTB. The presence of proteins in the PLs is expected to enhance the immune response against MTB

Methods

Results

Conclusion